

TMDA/DMC/MRE/F/016

Rev #:02



THE UNITED REPUBLIC OF TANZANIA

MINISTRY OF HEALTH



TANZANIA MEDICINES AND MEDICAL DEVICES AUTHORITY

PUBLIC ASSESSMENT REPORT FOR UTROGESTAN VAGINAL 100 AND UTROGESTAN VAGINAL 200 (PROGESTERONE 100 MG AND 200 MG) SOFT GELATIN CAPSULES

Version number 1.0

20 October 2023

**TMDA Headquarters, Plot No. 56/1, Block E, Kisasa B Centre, Hombolo Road, P. O. Box 1253,
Dodoma - Tanzania,**

Tel: +255 (26) 2961989/2061990/ +255(22) 2450512/2450751/2452108,

Email: info@tmda.go.tz, Website: www.tmda.go.tz, Toll free: 08001100834

1. Introduction

Utrogestan Vaginal is an innovator medicine/generic medicine of Progesterone Soft Gelatin Capsules. Utrogestan Vaginal is a progestin medicine belonging to G03DA04-Sex hormones and modulators of the genital system, progestogens. Utrogestan Vaginal 200 exerts its activity by mimicking the action of endogenous progesterone on the endometrium to convert the proliferating phase to the secretory phase. Utrogestan Vaginal is approved in Tanzania for use in adult women.

1.1 Product details

Registration number	Utrogestan Vaginal 100: TAN 20 HM 0350 Utrogestan Vaginal 200: TAN 20 HM 0406
Brand name	Utrogestan Vaginal 100 Utrogestan Vaginal 200
Generic name, strength and form	Progesterone 100 mg Soft Gelatin Capsules Progesterone 200 mg Soft Gelatin Capsules
ATC classification	G03DA04-Sex hormones and modulators of the genital system, progestogens
Distribution category	POM
Country of origin	Spain
Associated product	State any other product of formulation, strength or site that is linked or associated with the product if applicable
Marketing Authorization Holder	BESINS HEALTHCARE SA Avenue Louise 287, B-1050 Brussels Belgium Belgium
Local Technical Representative	CFAO Motor Complex, P.O. Box 70032, Sokoine, Plot No. 89-90 Nyerere Road, Dar es Salaam, Tanzania.

1.2 Assessment procedure

The application for registration of Utrogestan Vaginal 100/200 was submitted on 25/04/2019. The product underwent abridged assessment. Assessment was completed in 2 rounds of evaluation. Utrogestan Vaginal 100/200 was registered on 25/09/2020.

1.3 Information for users

Visual description of the finished product	Utrogestan Vaginal 100: Round, slightly yellow capsules containing whitish oily suspension Utrogestan Vaginal 200: Ovoid and slightly yellow capsules containing a whitish oily suspension
Primary packing material	PVC/ALU blister

Secondary packing materials	
Shelf-life and storage condition	36 Months Do not store above 30°C
Route of administration	Oral
Therapeutic indications	Subfertility or primary/secondary infertility due to partial or total luteal phase deficiency (in particular: poor ovulation, supplementation of the luteal phase during in vitro fertilisation, egg donations). Threat of miscarriage or prevention of recurrent miscarriages due to luteal phase deficiency.

2. Labelling and product information

Summary of product characteristics

The SmPC included all the relevant information to ensure correct and safe use of the medicine by healthcare providers. The complete SmPC can be accessed [here](#).

Package insert/leaflet

The package insert is confirmed to be derived from the SmPC and contains sufficient data for the end user. Since the product is POM that is intended for long term use the package insert contains both full prescribing information as per SmPC and simplified information for patients.

Container labels

The product label information is presented in English. Details in the secondary pack label include:

Brand name: Utrogestan Vaginal 200

Composition: Progesterone 200 mg soft capsules

Pack size: 21 capsules

Manufacturing details: batch number, expiry date

Storage conditions: <state the condition as it appears on the label>

Manufacturer address/MAH: Besins Healthcare, Avenue Louise 287, B-1050 Brussels Belgium

Unique identifier: <state the unique identification used>

Special warnings/precautions or instructions for use: <include warnings or IFU if applicable>

The details of the primary pack include:

Brand name and strength: Utrogestan Vaginal 200mg capsules

Manufacturing details: batch number, expiry date

Name of manufacturer/MAH: Besins Healthcare

The content of the primary and secondary labels was aligned to the requirements of the Part V of the Compendium: Guidelines on Format and Content of Product Labels for Medicinal products. The label contains sufficient information for proper identification of the medicine and post marketing follow up of the product.

Describe any approved deviation to the requirements and the justification for the deviation.

3. Scientific discussion

Quality of Active Pharmaceutical Ingredient(s)

Jiangsu Jiaerke Pharmaceuticals Group Corp, Ltd

Information on the quality of the API was submitted in form of CEP.


General properties

Progesterone API is compendia in BP/Ph.Eur.

Molecular formula: $C_{21}H_{30}O_2$

Chemical name: Pregn-4-ene-3, 20-Dione

Structure:



Critical physico-chemical properties of the API were practically insoluble in water, freely soluble in ethanol and sparingly soluble in acetone and in fatty oils. The API is micronized before manufacturing the finished product.

Manufacture

The API manufacturing site Jiangsu Jiaerke Pharmaceuticals Group Corp Ltd, Sanhuangmiao Zhenglu, Wujin, Changzhou, Jiangsu 213 111, China was noted to comply with WHO GMP requirements as evidenced by the GMP certificate issued by <state the issuing authority>. Progesterone API is manufactured by chemical synthesis using conventional techniques. Sufficient controls of quality of materials and in-process checks were employed throughout the manufacturing process.

Specifications

The API specifications were set as per BP standards and ICHQ3A. The parameters monitored during quality control are: appearance, identification, specific optical rotation, assay, related

substances, loss on drying, residual solvents, residual catalysts by AAS. Compliance to these specifications were established via batch analysis data and stability studies.

Stability and container closure system

The re-test period of Progesterone API is 36 months when packed in LDPE bag and stored at <storage conditions>.

Symbiotec Pharmalab Private Limited

Information on quality of the API was submitted in form of CEP.


General properties

Progesterone API is compendia in BP/Ph.Eur.

Molecular formula: $C_{21}H_{30}O_2$

Chemical name: Pregn-4-ene-3, 20-Dione

Structure:



Critical physico-chemical properties of the API were practically insoluble in water, freely soluble in ethanol and sparingly soluble in acetone and in fatty oils. The API exists in two polymorphic forms and is micronized before manufacturing the finished product.

Manufacture

The API manufacturing site Symbiotec Pharmalab Private Limited, Plot No. 5, 6, 7 & 8, Special Economic Zone Phase -II, Pharma Zone, District Dhar India-454 774 Pithampur, Madhya Pradesh, India was noted to comply with WHO GMP requirements as evidenced by the GMP certificate issued by <state the issuing authority>. Progesterone API is manufactured by chemical synthesis using conventional techniques. Sufficient controls of quality of materials and in-process checks were employed throughout the manufacturing process.

Specifications

The API specifications were set as per BP standards and ICHQ3A. The parameters monitored during quality control are: appearance, identification, specific optical rotation, assay, related

substances, loss on drying, residual solvents, residual catalysts by AAS. Compliance to these specifications were established via batch analysis data and stability studies.

Stability and container closure system

The re-test period of Progesterone API is 36 months when packed in LDPE bag and stored at <storage conditions>.

Quality of the Finished Pharmaceutical Product

Formulation

Utrogestan Vaginal 200 is a Ovoid and slightly yellow capsules containing a whitish oily suspension. Utrogestan Vaginal 200 contains micronized Progesterone and other ingredients listed hereafter sunflower oil, soybean lecithin, shell (gelatin, glycerol, titanium dioxide, purified water). The quantities of all ingredients are confirmed to be in line with the recommendations of Handbook of Pharmaceutical Excipients, Edition <number> in terms of function and quantities. Ingredient, <excipient> is of safety concern therefore appropriate warnings were included in the product label.

Manufacture

The finished product was manufactured at Cyndea Pharma, Poligono Industrial Emiliano Revilla Sanz - Avenida de Agreda, 31 - Olvega 42110 (Soria), Spain. The compliance of the site to TMDA GMP standards was confirmed through <site inspection/desk-review> on <date of GMP compliance>.

Specifications

The FPP is compendia in BP/USP/JP/International Ph>. The manufacturer controls the quality of the finished product as per <reference monograph(BP/USP/JP/International Ph/in-house)> and ICHQ3B requirements. The parameters monitored during quality control are: appearance, average mass of filled capsules, uniformity of dosage units, uniformity of capsule mass, micronized progesterone particle size, disintegration time, identification, assay, related substances, antimicrobial integrity. Compliance to the standard was established using batch analysis data and stability data.

Stability and container closure system

Stability studies were conducted on 3 batches of the finished product stored at 30°C ± 2°C / 75% RH ± 5% RH for 24 months and 40°C ± 2°C / 75% RH ± 5% RH for 6 months. Based on the stability data presented, the approved shelf-life is 36 months when stored in PVC/aluminium blister at below 30°C.

Safety and efficacy information

Safety and efficacy of Utrogestan Vaginal 100/200 was established through regulatory reliance as the product is registered in countries with stringent regulatory authorities (SRAs) and in the country of origin, Spain.

4. Benefit-Risk Assessment and Conclusion

On basis of the data submitted, the current state of knowledge and compliance to Good Manufacturing Practice, the benefit of the product outweighs the risks associated with its use when used in accordance to the summary of product characteristics. Utrogestan Vaginal 100/200 is recommended for registration.

5. Post-approval updates

Variation applications

Reference number	Date submitted	Change requested	Recommendation	Granting date

Feedback from pharmacovigilance, post marketing surveillance and enforcement activities

Type of feedback	Impact	Response

Re-registration applications

Application for renewal of registration was submitted on <DDMMYYYY>. The application was finalized in <number> rounds of evaluation. The product was confirmed to still be compliant to the standards of quality, safety and efficacy, hence registration was renewed on <DDMMYYYY>.

PART 5: CHANGE HISTORY

Version number	Date	Description of update	Section(s) Modified	Approval date

Annex I: Mock up label

Utrogestan Vaginal 200

